01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
18:33 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer Mouse studies suggest antibodies against the conserved α3 domain of MICA and MICB could help treat metastatic melanoma and colorectal cancer. In mouse models of metastatic melanoma and colon cancer, a mAb...
13:14 , Mar 30, 2018 |  BC Extra  |  Preclinical News

Targeting stress proteins on cells to help treat cancer

Researchers at the Dana-Farber Cancer Institute identified a mAb that binds to a domain on stress proteins expressed by cancer cells, thereby impeding the cancer from sloughing off the protein to escape natural killer cells....
22:57 , Jun 29, 2017 |  BC Innovations  |  Product R&D

Drop the MIC

Two start-ups have joined the wave of companies harnessing NK cell biology to generate new immunotherapies for cancer by focusing on the relatively unexplored ligands for the NK cell receptor NKG2D. Having laid low for...
07:00 , Jul 28, 2016 |  BC Innovations  |  Tools & Techniques

Innate harmony

On the heels of cancer immunotherapy's clinical success, NK cells - a long-known but underappreciated component of the innate immune system - are emerging as the hottest new tool to fight cancer, with the potential...
07:00 , Apr 28, 2016 |  BC Innovations  |  Finance

Public-Private Partnership Roundup

Public-private partnerships (PPPs) continue to accumulate at a high rate in the preclinical space, with 56 deals disclosed in 1Q16, but the data suggest the nature of the deals is moving away from large disease-centric...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Company News

Marina Biotech, Microlin Bio deal

Microlin will acquire “substantially all” of Marina’s assets for $1 million in cash and 6.7 million shares valued at $10.1 million based on Microlin’s close of $1.50 before the deal was announced. The deal includes...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Company News

Universite Laval, Microlin Bio deal

Microlin and the university partnered to co-develop microRNA-based therapies for Alzheimer’s disease (AD). Microlin will have exclusive, worldwide rights to develop and commercialize resulting compounds and methods. Microlin declined to provide financial details, and the...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer MHC class I polypeptide-related sequence B (MICB); killer cell lectin-like receptor subfamily...